clinic
sign
acut
system
sign
ill
symptomat
therapi
often
take
preced
achiev
precis
diagnosi
durat
clinic
sign
chronic
week
system
sign
ill
determin
effort
made
achiev
specif
diagnosi
diarrhea
companion
anim
may
develop
one
pathophysiolog
mechan
one
mechan
tend
predomin
small
intestin
bacteri
overgrowth
sibo
exocrin
pancreat
insuffici
epi
best
exampl
lumin
maldigest
companion
anim
sibo
antibioticrespons
diarrhea
epi
induc
maldigest
steatorrhea
diarrhea
bacteri
degrad
pancreat
enzym
sibo
insuffici
enzym
secret
epi
fat
maldigest
steatorrhea
may
also
result
defici
bile
salt
secret
eg
intraor
extrahepat
cholestasi
abnorm
enterohepat
recircul
bile
salt
eg
portosystem
vascular
shunt
atrophi
villou
absorpt
surfac
area
occur
mani
patholog
process
atrophi
caus
acceler
loss
enterocyt
decreas
product
enterocyt
stem
cell
crypt
stem
cell
retain
abil
reconstitut
overli
mucosa
regener
may
take
day
week
depend
upon
patholog
process
viral
infect
eg
parvoviru
coronaviru
rotaviru
import
caus
damag
villu
enterocyt
dog
cat
viral
enteritid
usual
acut
selflimit
infect
resolv
matter
day
week
villou
atrophi
may
result
immunemedi
process
glutensensit
enteropathi
irish
setter
dog
consequ
food
sensit
reaction
dog
cat
food
sensit
reaction
increasingli
recogn
import
caus
villou
atrophi
malassimil
diarrhea
companion
anim
immunosuppress
drug
eg
glucocorticoid
vincristin
azathioprin
cyclophosphamid
may
also
caus
sever
villou
atrophi
glucocorticoid
frequent
prescrib
manag
inflammatori
bowel
diseas
ibd
antiinflammatori
dose
glucocorticoid
appear
minim
effect
epitheli
cell
turnov
immunosuppress
dose
may
abolish
epitheli
cell
renew
effect
usual
revers
discontinu
therapi
enterocyt
dysfunct
common
find
mani
primari
gastrointestin
disord
dog
cat
enterocyt
dysfunct
may
seen
inflamm
infect
malnutrit
malign
ischemia
certain
drug
therapi
eg
misoprostol
gastrointestin
tract
patholog
induc
enterocyt
dysfunct
imped
cl
transport
na
glucos
cotransport
voltagedepend
calcium
channel
compon
cell
signal
transduct
pathway
sibo
major
caus
brushbord
membran
damag
canin
intestin
hydrolas
brushbord
transport
protein
degrad
bacteria
particularli
anaerob
prolifer
small
intestin
bacteria
damag
brushbord
usual
revers
follow
appropri
antimicrobi
therapi
similar
brushbord
membran
maldigest
document
canin
ibd
chang
also
readili
revers
resolut
ibd
specif
brushbord
membran
malabsorpt
document
giant
schnauzer
cobalamin
defici
malabsorpt
stomach
evolv
mucos
barrier
properti
reduc
deleteri
effect
gastric
acid
intestin
evolv
mucos
barrier
properti
exclud
bacteri
pathogen
maintain
oral
toler
barrier
disrupt
may
caus
moder
sever
inflamm
ulcer
ischemia
cytotox
drug
certain
proteinlos
state
inflammatori
mediat
tumor
necrosi
plateletactiv
factor
mediat
effect
mucos
barrier
disrupt
role
dietari
hypersensit
reaction
pathogenesi
canin
felin
chronic
diarrhea
incomplet
understood
although
recent
studi
suggest
advers
reaction
food
antigen
common
dog
cat
chronic
diarrhea
true
allergi
immunoglobulin
emedi
reaction
appear
rare
best
clinic
outcom
obtain
definit
diagnosi
specif
therapi
see
section
vi
cat
intestin
lymphoma
exampl
better
outcom
correctli
diagnos
treat
chemotherapi
similarli
german
shepherd
dog
diarrhea
steatorrhea
weight
loss
raven
appetit
much
better
outcom
correctli
diagnos
epi
appropri
medic
pancreat
replac
enzym
definit
diagnosi
specif
therapi
may
possibl
case
especi
true
case
ibd
sequenti
nonspecif
therapi
may
need
control
mild
sever
clinic
sign
box
pet
owner
may
permit
detail
medic
investig
definit
diagnosi
may
reach
despit
detail
appropri
medic
investig
case
would
entir
appropri
consid
nonspecif
form
therapi
criteria
commenc
nonspecif
therapi
includ
diarrhea
chronic
frequent
andor
sever
b
definit
diagnosi
forthcom
c
client
desir
definit
diagnosi
dietari
therapi
precis
immunolog
mechan
canin
felin
ibd
yet
determin
prevail
hypothesi
develop
ibd
loss
immunolog
toler
normal
bacteri
flora
food
antigen
accordingli
dietari
modif
may
prove
use
manag
canin
felin
ibd
sever
nutrit
strategi
propos
manag
gastrointestin
tract
diseas
includ
novel
protein
hydrolyz
diet
antioxid
diet
prebiot
mediumchain
companion
anim
food
hypersensit
reaction
may
evok
gener
inflammatori
respons
involv
histamin
leukotrien
prostaglandin
substanc
p
serotonin
effect
gastrointestin
absorpt
secret
permeabl
motil
inflamm
major
caus
chronic
diarrhea
dog
cat
although
gut
inflamm
may
induc
mani
differ
incit
caus
eg
dietari
antigen
bacteri
pathogen
toxin
neoplasia
experiment
studi
suggest
immun
respons
initi
sustain
result
exposur
dietari
antigen
andor
indigen
gut
bacteria
cellular
compon
b
lymphocyt
plasma
cell
macrophag
molecular
element
prostaglandin
leukotrien
complement
plateletactiv
factor
nitric
oxid
oxygenderiv
free
radic
contribut
mucos
inflammatori
respons
clinic
sign
ibd
diarrhea
vomit
anorexia
somewhat
relat
sever
mucos
cellular
infiltr
inflammatori
mediat
function
abnorm
eg
chang
permeabl
motil
gut
may
contribut
clinic
sign
mani
anim
intestin
neoplasia
may
induc
diarrhea
sever
pathophysiolog
mechan
includ
obstructioninduc
fluid
secret
releas
bioactiv
substanc
eg
histamin
diffus
mast
cell
diseas
intestin
carcinoid
gastrin
gastrinoma
bacteri
prolifer
overgrowth
protein
lipid
exud
reduct
normal
villou
absorpt
surfac
area
lymphang
intestin
lymphangiectasia
common
lymphat
transport
disord
dog
lymphangiectasia
fairli
common
dog
rare
cat
lymphangiectasia
may
occur
primari
congenit
disord
frequent
may
develop
secondarili
ibd
neoplast
infiltr
rightsid
heart
failur
diarrheal
disord
result
one
pathogen
mechan
other
may
sever
concurr
pathogen
mechan
exampl
maldigest
malabsorpt
excess
secret
chang
permeabl
protein
lipid
exud
disord
motil
epi
often
regard
classic
maldigest
disord
absenc
pancreat
enzym
secret
undigest
protein
lipid
carbohydr
absorb
affect
anim
develop
diarrhea
steatorrhea
sever
proteincalori
malnutrit
anim
develop
sibo
gastric
acidinduc
injuri
intestin
mucosa
cobalamin
malabsorpt
hypersecret
fluid
electrolyt
reason
pancreat
insuffici
anim
may
incomplet
respons
pancreat
enzym
replac
therapi
bacteri
infect
anoth
exampl
diarrheal
disord
multipl
pathophysiolog
mechan
heatstabl
enterotoxin
enteropathogen
escherichia
coli
stimul
guanyl
cyclas
product
cyclic
guanosin
monophosph
cgmp
activ
cgmpdepend
protein
kinas
culmin
secretorytyp
diarrhea
time
plateletactiv
factor
prostaglandin
leukotrien
produc
bacteri
infect
may
contribut
malabsorpt
disord
motil
e
coli
infect
l
rhamnosu
gg
safe
colon
canin
gastrointestin
tract
although
probiot
effect
canin
intestin
firmli
establish
probiot
organ
enterococcu
faecium
safe
colon
canin
gastrointestin
tract
shown
increas
fecal
immunoglobulin
content
circul
matur
b
major
histocompat
complex
class
ii
cell
young
puppi
suggest
probiot
may
use
prevent
treatment
canin
gastrointestin
diseas
organ
may
howev
enhanc
campylobact
jejuni
adhes
colon
dog
intestin
perhap
confer
carrier
statu
colon
dog
lactobacillu
acidophilu
also
shown
safe
colon
canin
gastrointestin
tract
major
physiolog
function
small
intestin
lumin
brushbord
digest
secret
absorpt
see
chapter
physiolog
properti
small
intestin
exampl
motil
blood
flow
evolv
regul
digest
secret
absorpt
anatom
structur
support
function
includ
serosa
longitudin
smooth
muscl
myenter
auerbach
plexu
circular
smooth
muscl
submucos
meissner
plexu
musculari
mucosa
mucosa
epitheli
cell
intestin
mucosa
special
primarili
membran
brushbord
enzymat
eg
disaccharidas
peptidas
digest
fluid
electrolyt
secret
absorpt
crypt
germin
center
intestin
epithelium
crypt
epitheli
cell
primarili
secretori
functionwat
solut
bicarbon
secret
intestin
lumen
solubil
chyme
neutral
gastric
acid
reduc
bacteri
microflora
cell
migrat
intestin
villi
matur
absorpt
cell
villu
epitheli
cell
primarili
absorpt
functionwat
solut
glucos
monosaccharid
amino
acid
small
peptid
free
fatti
acid
glycerol
miner
vitamin
nutrient
absorb
lumen
villu
epitheli
cell
submucos
plexu
neuron
innerv
overli
mucosa
regul
absorpt
secret
villu
crypt
epitheli
cell
respect
myenter
plexu
neuron
innerv
longitudin
circular
smooth
muscl
layer
regul
intestin
motil
contract
longitudin
smooth
muscl
stimul
peristalt
type
activ
net
fluid
transit
contract
circular
smooth
muscl
mediat
segment
type
activ
delay
fluid
transit
health
villu
epitheli
cell
activ
absorb
na
cl
passiv
absorb
h
see
fig
malabsorpt
disord
na
cl
h
absorpt
often
markedli
reduc
villu
epitheli
cell
absorpt
may
inhibit
number
mechan
includ
effect
prostaglandin
eg
prostaglandin
e
leukotrien
cyclic
nucleotid
cyclic
adenosin
monophosph
cgmp
serotonerg
serotonin
vasoact
intestin
polypeptid
receptor
activ
stimul
absorpt
cell
hand
mediat
noradrenerg
norepinephrin
opioid
receptor
activ
pathophysiolog
malabsorpt
disord
serv
basi
medic
therapi
prostaglandin
synthetas
inhibitor
agonist
serotonerg
antagonist
noradrenerg
agonist
see
fig
health
crypt
epitheli
cell
activ
secret
cl
hco
h
see
fig
hypersecretori
disord
cl
h
secret
often
markedli
increas
crypt
epitheli
cell
triglycerid
supplement
lowfat
diet
modif
fatti
acid
ratio
fiber
supplement
strategi
evidencebas
medicin
emerg
use
novel
protein
hydrolyz
antioxid
supplement
prebiot
diet
novel
protein
food
sensit
reaction
suspect
document
cat
present
gastroenterolog
problem
without
concurr
dermatolog
problem
prospect
studi
advers
food
reaction
cat
beef
wheat
corn
gluten
primari
ingredi
respons
food
sensit
reaction
studi
cat
respond
feed
chickenor
venisonbas
selectedprotein
diet
minimum
week
author
conclud
advers
reaction
dietari
stapl
common
cat
chronic
gastrointestin
problem
success
manag
feed
selectedprotein
diet
support
concept
come
studi
gastroenterolog
dermatolog
clinic
sign
significantli
improv
feed
novel
protein
evid
accru
hydrolyz
diet
may
use
nutrit
manag
canin
ibd
conceptu
basi
hydrolyz
diet
oligopeptid
insuffici
size
structur
induc
antigen
recognit
present
one
preliminari
studi
dog
ibd
show
signific
improv
follow
feed
hydrolyz
diet
although
fail
respond
feed
novel
protein
clinic
improv
could
sole
attribut
hydrolyz
natur
protein
sourc
test
diet
modifi
featur
high
digest
cornstarch
rather
intact
grain
medium
chain
triglycerid
alter
ratio
polyunsatur
fatti
acid
addit
studi
requir
ascertain
efficaci
nutrit
strategi
manag
ibd
experiment
ibd
dog
accompani
signific
abnorm
normal
gastrointestin
motil
physic
exercis
shown
disrupt
jejun
ileal
colon
migrat
motor
complex
increas
total
durat
contract
organ
nonmigr
motor
complex
fed
state
exercis
also
induc
giant
migrat
contract
defec
mass
movement
fast
fed
state
increas
motor
activ
intestin
colon
extra
giant
migrat
contract
result
physic
exercis
may
aid
normal
gastrointestin
motor
function
ibd
case
initi
true
enter
pathogen
wherea
other
complic
sibo
ibd
case
may
show
shortterm
respons
one
antibiot
exampl
tylosin
metronidazol
oxytetracyclin
probiot
live
organ
low
pathogen
exert
benefici
effect
eg
stimul
innat
acquir
immun
health
host
gramposit
commens
lactic
acid
bacteria
eg
lactobacilli
mani
benefici
health
effect
includ
enhanc
lymphocyt
prolifer
innat
acquir
immun
antiinflammatori
cytokin
product
lactobacillu
rhamnosu
gg
bacterium
use
product
adrenerg
antagonist
drug
must
use
care
activ
adrenerg
receptor
chemoreceptor
trigger
zone
caus
vomit
clonidin
dose
bidtid
sqpo
best
exampl
classif
mix
agonist
loperamid
stimul
fluid
electrolyt
absorpt
stimul
segmentationtyp
intestin
motil
loperamid
mgkg
po
may
benefici
treatment
difficult
refractori
case
ibd
glucocorticoid
antiinflammatori
immunosuppress
dose
prednison
prednisolon
may
use
treat
ibd
dog
fail
respond
dietari
manag
sulfasalazin
metronidazol
adjunct
therapi
dietari
modif
felin
ibd
prednison
prednisolon
use
frequent
short
durat
action
costeffect
wide
avail
equipot
dose
dexamethason
equal
effect
may
deleteri
effect
brushbord
enzym
activ
prednison
use
week
depend
upon
sever
clinic
sign
higher
dose
prednison
eg
mgkg
po
daili
may
need
control
sever
form
eosinophil
coliti
hypereosinophil
syndrom
cat
combin
therapi
sulfasalazin
metronidazol
azathioprin
may
reduc
overal
dosag
prednison
need
achiev
remiss
clinic
sign
sulfasalazin
dose
glucocorticoid
may
reduc
interv
hope
maintain
remiss
dietari
modif
steroid
side
effect
suppress
hypothalamicpituitaryadren
axi
sever
altern
glucocorticoid
develop
excel
topic
ie
mucos
antiinflammatori
activ
significantli
metabol
first
pass
hepat
metabol
budesonid
use
mani
year
inhal
medic
asthma
entericco
form
drug
avail
treatment
ibd
human
anim
littl
evidencebas
medicin
support
use
medic
canin
felin
ibd
dose
mgm
po
daili
everi
day
use
success
anecdot
case
azathioprin
purin
analogu
follow
dna
incorpor
inhibit
lymphocyt
activ
prolifer
rare
effect
singl
agent
instead
use
adjunct
therapi
glucocorticoid
azathioprin
may
signific
steroidspar
effect
ibd
dose
mgkg
po
dog
mgkg
po
cat
use
success
ibd
may
take
sever
week
month
therapi
azathioprin
becom
maxim
effect
cat
particularli
monitor
side
effect
includ
myelosuppress
hepat
diseas
acut
pancreat
necrosi
cyclosporin
use
renal
transplant
patient
inhibitori
effect
tcell
function
recent
time
cyclosporin
use
number
immunemedi
disord
includ
keratoconjunct
sicca
perian
fistula
anal
furunculosi
immunemedi
hemolyt
anemia
anecdot
report
pharmacolog
secretori
crypt
cell
remark
similar
absorpt
villu
cell
thu
crypt
epitheli
cell
secret
may
stimul
prostaglandin
eg
prostaglandin
e
leukotrien
cyclic
nucleotid
cyclic
adenosin
monophosph
cgmp
serotonerg
serotonin
vasoact
intestin
polypeptid
receptor
activ
see
fig
inhibit
secret
cell
hand
mediat
noradrenerg
norepinephrin
opioid
receptor
activ
pathophysiolog
hypersecretori
disord
serv
basi
medic
therapi
exampl
prostaglandin
synthetas
inhibit
serotonerg
receptor
antagon
noradrenerg
receptor
agon
receptor
agon
see
fig
sulfasalazin
highli
effect
prostaglandin
synthetas
inhibitor
proven
efficaci
therapi
larg
bowel
ibd
dog
sulfasalazin
compound
molecul
mesalamin
formerli
sulfapyridin
link
azo
chemic
bond
follow
oral
dose
sulfasalazin
transport
distal
gastrointestin
tract
cecal
colon
bacteria
meta
boliz
drug
compon
part
sulfapyridin
larg
absorb
colon
mucosa
much
remain
colon
lumen
inhibit
mucos
lipoxygenas
inflammatori
cascad
sulfasalazin
recommend
treatment
canin
larg
bowel
ibd
dose
mgkg
po
week
resolut
clinic
sign
sulfasalazin
dosag
gradual
decreas
interv
eventu
discontinu
maintain
dietari
manag
salicyl
readili
absorb
induc
toxic
cat
therefor
drug
classif
use
great
caution
cat
use
cat
author
recommend
use
half
recommend
dog
dose
ie
mgkg
po
sulfasalazin
usag
associ
develop
keratoconjunct
sicca
dog
tear
product
assess
subject
pet
owner
object
veterinarian
usag
drug
classif
develop
reduc
toxic
sulfapyridin
portion
parent
molecul
sulfasalazin
enhanc
efficaci
mesalamin
dipentum
asacol
dimesalamin
olsalazin
avail
use
treatment
canin
larg
bowel
ibd
olsalazin
use
dosag
mgkg
po
dog
despit
formul
sulfafre
prepar
instanc
keratoconjunct
sicca
still
report
dog
drug
stimul
circular
smooth
muscl
contract
therefor
intestin
segment
loperamid
concurr
stimul
absorpt
inhibit
secret
fluid
electrolyt
loperamid
dose
mgkg
po
prefer
drug
categori
antagonist
neuron
receptor
inhibit
cl
h
secret
intestin
epitheli
cell
exampl
drug
classif
includ
ondansetron
zofran
glaxo
dose
mgkg
bid
po
granisetron
kytril
smithklin
beecham
dose
mgkg
po
iv
tropisetron
navoban
novarti
dose
mgkg
bid
po
dolasetron
anzemet
sanofiaventi
dose
mgkg
bid
po
iv
sq
suggest
cyclosporin
mgkg
po
daili
may
use
treatment
case
refractori
ibd
evidencebas
medicin
studi
need
establish
efficaci
anecdot
experi
suggest
cyclosporin
may
use
difficult
refractori
case
ibd
modifi
formul
cyclosporin
ie
cyclosporinemodifi
prefer
origin
unmodifi
formul
chlorambucil
chlorambucil
mgm
po
everi
day
use
place
azathioprin
difficult
refractori
case
felin
ibd
ibd
irrit
bowel
syndrom
like
underli
behavior
compon
abnorm
person
trait
potenti
environment
stress
factor
identifi
dog
one
studi
multipl
factor
present
affect
household
includ
travel
reloc
hous
construct
separ
anxieti
submiss
urin
nois
sensit
aggress
role
behavior
pathogenesi
therapi
canin
felin
gastrointestin
disord
remain
larg
unexplor
see
chapter
report
indic
shortterm
prognosi
control
ibd
good
excel
follow
complet
drug
therapi
mani
anim
abl
maintain
remiss
sign
dietari
manag
alon
treatment
failur
uncommon
usual
result
incorrect
diagnosi
especi
import
rule
alimentari
lymphosarcoma
b
presenc
sever
diseas
histiocyt
ulcer
coliti
proteinlos
enteropathi
irrevers
mucosa
lesion
fibrosi
c
poor
client
complianc
appropri
drugdietari
recommend
use
inappropri
drug
nutrit
therapi
e
presenc
concurr
diseas
sibo
hepatobiliari
diseas
prognosi
cure
ibd
poor
relaps
anticip
